SURPASS-CVOT Results: How Does Tirzepatide Stack Up Against Dulaglutide for Cardiovascular Health? Published: December 17, 2025 | Source: New England Journal of Medicine Tirzepatide, the dual GIP and GLP-1 receptor agonist, has already made waves for its potent effects on … Read More
weight loss
SELECT Trial: Semaglutide and CV outcomes
Semaglutide Improve CV events? SELECT Trial Summary The SELECT trial, a pivotal study published in the New England Journal of Medicine (NEJM) in November 2023, has offered the medical community valuable insights into the treatment of cardiovascular (CV) events in … Read More
SURMOUNT-1 Trial: Tirzepatide for Weight Loss in Obesity
2022 SURMOUNT-1 TRIAL M Tirze patide Once Weekly for the Treatment of Obesity Phase 3 double-blind, randomized, controlled trial Objective: To assess the efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and GLP-1 agonist, in treatment of obesity … Read More